Skip to Main Content

Advertisement

Current Issue
Volume 3,
Issue 21,
November 12, 2019

Featured Content

Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia

The BCL2 inhibitor venetoclax has recently been approved for the treatment of older patients with acute myeloid leukemia. Real-world experience with this drug is important to validate the activity of this agent and was explored by Pollyea and colleagues, who compared outcomes of patients treated with venetoclax and azacytidine to a cohort of patients treated on a clinical trial.

Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin disease

Cold agglutinin disease is a rare hemolytic anemia that is poorly understood. Berentsen and colleagues utilized the Danish National Patient Registry to identify its incidence, risk of thromboembolic events, and mortality compared to a matched cohort.

Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis

Novel drugs and autologous transplantation are part of the reasons why overall outcomes for patients with multiple myeloma continue to improve. Ailawadhi and colleagues explored racial disparities in treatment patterns in a report with sobering findings.

Role of coagulation system in the pathogenesis of sickle cell disease

The vascular complications of sickle cell disease are well recognized and of great clinical importance. In a review article, Nasimuzzaman and Malik discuss the role of the coagulation system in sickle cell disease pathogenesis. We hope you find this comprehensive review useful and informative.

Megakaryocytes package contents into separate α-granules that are differentially distributed in platelets

A number of important biological functions have been attributed to platelets ranging from hemostasis to inflammation. Many of these functions are impacted by distinct proteins targeted in α-granules. In an interesting study, Italiano Jr. and colleagues explored the differential packaging of discrete bioactive contents during megakaryocyte differentiation into platelets to help explain this fascinating biology.

Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia

Allogeneic hematopoietic cell transplantation has been a highly successful therapy for the treatment of patients with severe aplastic anemia. Eapen and colleagues analyzed a large number of patients to explore the preparative regimen for optimal outcomes.

Close Modal
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close Modal
Close Modal

Advertisement